AC Immune SA
ACIU
$1.68
$0.021.21%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -3.61% | -235.75% | 137.11% | -34.41% | -7.94% |
| Total Depreciation and Amortization | 7.06% | -3.89% | -1.61% | 0.70% | 3.23% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 746.45% | -144.58% | -243.74% | 432.74% | -85.67% |
| Change in Net Operating Assets | -112.33% | 254.20% | -4,257.27% | 18,413.93% | 1,405.81% |
| Cash from Operations | -1,887.09% | 136.95% | -8.59% | 614.26% | 106.45% |
| Capital Expenditure | -41.40% | 45.33% | 38.36% | 56.38% | -31.79% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 114.14% | -116.07% | -139.17% | -1,405.96% | -157.38% |
| Cash from Investing | 112.50% | -116.57% | -145.15% | -1,361.97% | -158.26% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -51.50% | -23.02% | -23.74% | -28.15% | -23.70% |
| Issuance of Common Stock | -- | -- | -- | -93.44% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 99.04% | -- | -100.00% | -242.86% | -8,616.67% |
| Cash from Financing | 63.53% | -100.48% | -139.43% | -103.22% | -416.34% |
| Foreign Exchange rate Adjustments | -115.03% | 226.66% | -5,486.25% | -3,531.14% | 18,526.85% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 26.15% | -91.65% | -141.97% | 68.94% | -187.97% |